Under terms of the deal, AbbVie will acquire Capstan’s lead asset, CPTX2309—an in vivo anti-CD19 CAR T-cell therapy in Phase ...

Gubra, founded in 2008 in Denmark, listed on Nasdaq Copenhagen, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. Gubra ...

HORSHOLM, DENMARK / ACCESS Newswire / June 27, 2025 / On Friday, 27 June 2025 at 12:00 am (CEST), an extraordinary general meeting of Gubra A/S (CPH:GUBRA) (the "Company") was held at the Company's ...

This Big Pharma stock is one of the safest bets, according to the Mad Money host, and it plays an attractive dividend to ...

Gubra should focus on what they are good at - biotech research. Instead of investing the extra cash itself, Gubra sends the money back to the company’s owners - the shareholders. This makes sense ...

Gubra reported Q1 2025 revenue of DKK 7 million, representing a 7% year-over-year increase. However, this figure does not include the $350 million (approximately DKK 2.4 billion) upfront payment from ...

Gubra’s first quarter was defined by the landmark exclusive global license agreement with AbbVie for GUBamy, a long-acting amylin analogue for obesity treatment.

Gubra, founded in 2008 in Denmark, listed on Nasdaq Copenhagen, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases.

Gubra, founded in 2008 in Denmark, listed on Nasdaq Copenhagen, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases.

Gubra noted that the observed body weight loss trend aligned with data from the prior SAD study. Furthermore, the study confirmed GUBamy’s favorable half-life of 11 days (270 hours).

Gubra, founded in 2008 in Denmark, listed on Nasdaq Copenhagen, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases.

Gubra, founded in 2008 in Denmark, listed on Nasdaq Copenhagen, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases.